SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001305253-23-000011
Filing Date
2023-05-11
Accepted
2023-05-11 16:15:45
Documents
60
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eigr-20230331.htm   iXBRL 10-Q 1308576
2 EX-31.1 eigr-2023x03x31ex311.htm EX-31.1 9810
3 EX-31.2 eigr-2023x03x31ex312.htm EX-31.2 9801
4 EX-32.1 eigr-2023x03x31ex321.htm EX-32.1 5445
  Complete submission text file 0001305253-23-000011.txt   5865439

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eigr-20230331.xsd EX-101.SCH 39453
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT eigr-20230331_cal.xml EX-101.CAL 61327
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT eigr-20230331_def.xml EX-101.DEF 188802
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eigr-20230331_lab.xml EX-101.LAB 526099
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eigr-20230331_pre.xml EX-101.PRE 332914
54 EXTRACTED XBRL INSTANCE DOCUMENT eigr-20230331_htm.xml XML 851356
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36183 | Film No.: 23911234
SIC: 2836 Biological Products, (No Diagnostic Substances)